Mycophenolate mofetil

被引:79
作者
Zwerner, Jeffrey [1 ]
Fiorentino, David [1 ]
机构
[1] Stanford Univ, Dept Dermatol, Palo Alto, CA 94304 USA
关键词
Cellcept (TM); dermatology; immunomodulators; immunosuppressive; mycophenolate mofetil;
D O I
10.1111/j.1529-8019.2007.00136.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Mycophenolate mofetil (MMF) is a relatively new systemic immunosuppressive agent whose use is rapidly increasing within the field of dermatologic. Originally used in the 1970s for the treatment of psoriasis, MMF has demonstrated efficacy in multiple types of inflammatory skin diseases. Although the safety data within the dermatologic literature is sparse, MMF's extensive use within the field of organ transplantation has demonstrated a favorable safety profile. MMF's lack of hepatic or renal toxicity is a significant advantage over immunosuppressive medications currently used in dermatology and make MMF an attractive candidate for multidrug regimens. In this review the present authors discuss the pharmacology, mechanisms of action, side effects and current uses of MMF reported within the dermatologic literature. The present authors also provide practical information regarding the use of the MMF culled from the literature as well as from the present authors' own clinical experience with the medication.
引用
收藏
页码:229 / 238
页数:10
相关论文
共 94 条
[31]   Severe recalcitrant pyoderma gangrenosum responding to a combination of mycophenolate mofetil with cyclosporin and complicated by a mononeuritis [J].
Gilmour, E ;
Stewart, DG .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (02) :397-400
[32]   Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects [J].
Gimenez, F ;
Foeillet, E ;
Bourdon, O ;
Weller, S ;
Garret, C ;
Bidault, R ;
Singlas, E .
CLINICAL PHARMACOKINETICS, 2004, 43 (10) :685-692
[33]  
GOLDBLUM R, 1993, CLIN EXP RHEUMATOL, V11, pS117
[34]   CUTANEOUS BETA-GLUCURONIDASE - CLEAVAGE OF MYCOPHENOLIC-ACID BY PREPARATIONS OF MOUSE SKIN [J].
GOMEZ, EC ;
MICHAELOVER, J ;
FROST, P .
BRITISH JOURNAL OF DERMATOLOGY, 1977, 97 (03) :303-306
[35]   EFFICACY OF MYCOPHENOLIC-ACID FOR THE TREATMENT OF PSORIASIS [J].
GOMEZ, EC ;
MENENDEZ, L ;
FROST, P .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1979, 1 (06) :531-537
[36]   Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil [J].
Goyal, S ;
Nousari, HC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (01) :142-144
[37]  
Grundmann-Kollman M, 2001, ARCH DERMATOL, V137, P870
[38]   Mycophenolate mofetil:: A new therapeutic option in the treatment of blistering autoimmune diseases [J].
Grundmann-Kollmann, M ;
Korting, HC ;
Behrens, S ;
Kaskel, P ;
Leiter, U ;
Krähn, G ;
Kerscher, M ;
Peter, RU .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (06) :957-960
[39]   Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil [J].
Grundmann-Kollmann, M ;
Mooser, G ;
Schraeder, P ;
Zollner, T ;
Kaskel, P ;
Ochsendorf, F ;
Boehncke, WH ;
Kerscher, M ;
Kaufmann, R ;
Peter, RU .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (05) :835-837
[40]   Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation [J].
Hambach, L ;
Stadler, M ;
Dammann, E ;
Ganser, A ;
Hertenstein, B .
BONE MARROW TRANSPLANTATION, 2002, 29 (11) :903-906